Admin, Author at Halberd Corporation

About Admin

This author has not yet filled in any details.
So far Admin has created 165 blog entries.

Dec 20 2021

Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases

By Admin|2021-12-19T18:05:14-05:00December 20th, 2021|Investor News, Medical, News|0 Comments

Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid Jackson Center, PA, December 20, 2021 – Halberd Corporation (OTC PINK:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Halberd has also completed confirmatory tests on the elimination of all the previously tested cytokines (see table below). Interleukin-2 ...

Dec 15 2021

Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases

By Admin|2021-12-14T20:33:30-05:00December 15th, 2021|Investor News, Medical, News|0 Comments

Jackson Center, PA, December 15, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-12 is a pro-inflammatory cytokine which has recently been identified at elevated levels in patients with Alzheimer’s Disease or mild cognitive impairment. Halberd’s demonstrated ability to control the ...

Dec 13 2021

Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases

By Admin|2021-12-12T18:23:45-05:00December 13th, 2021|Featured, Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, December 13, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer’s Disease. Halberd’s demonstrated ability to control the levels of IL-1, coupled with its previous ...

Dec 6 2021

Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer’s Disease and PTSD/CTE

By Admin|2021-12-05T19:03:46-05:00December 6th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, December 6, 2021 – Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF). These tests confirmed virtually 100% elimination of TNF-alpha through Halberd’s patented extracorporeal process, in combination with its patent-pending exposure to tuned laser irradiation. TNF-alpha is an inflammatory cytokine ...

Nov 22 2021

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease

By Admin|2021-11-21T20:32:25-05:00November 22nd, 2021|Investor News, News, Press Releases|0 Comments

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease Jackson Center, PA, November 22, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through Halberd’s patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated ...

Nov 8 2021

Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves

By Admin|2021-11-07T19:56:42-05:00November 8th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, November 8, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves. Previously, Halberd filed a provisional patent application on this treatment method. Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd’s ...

Nov 1 2021

Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease

By Admin|2021-10-31T17:47:07-04:00November 1st, 2021|Featured, Investor News, Medical, News|0 Comments

Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer’s Disease. Jackson Center, PA, November 1, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through its patented extracorporeal process in combination with its patent-pending laser eradication ...

Oct 25 2021

Halberd Files Provisional Patent on Breakthrough Obesity Treatment

By Admin|2021-10-24T19:32:33-04:00October 25th, 2021|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, October 25, 2021 – Halberd Corporation (OTC-PINK: HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the various proteins, cytokines and antigens associated with obesity. Removal of these obesity-related target elements would reduce or eliminate ...

Oct 20 2021

Halberd’s PTSD/Alzheimer’s R&D Reveals Link to Potential Obesity Cure

By Admin|2021-10-19T21:30:49-04:00October 20th, 2021|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, October 20, 2021 – Halberd Corporation’s (OTC-PINK: HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer’s Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity. Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in ...

Oct 12 2021

Halberd and GTX Corp Sign Scientific Collaboration and Reseller Agreement

By Admin|2021-10-11T21:52:59-04:00October 12th, 2021|Featured, Investor News, News|0 Comments

GTX and Halberd will begin collaborating on developing and testing treatments for Alzheimer’s Disease/PTSD and other neurological diseases and GTX will begin marketing Halberd’s VitaShieldMaxTM Immune Support through their online ecommerce platform. Jackson Center, PA, October 12, 2021 – Halberd Corporation (OTC-PINK: HALB) and GTX Corp (OTC-PINK: GTXO) have agreed to work together on various ...

Previous 789 Next

jborza

About Admin